The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Abstract
Purpose: To evaluate efficacy and toxicity of cetuximab plus carboplatin in recurrent or metastatic nasopharyngeal carcinoma (NPC) resistant to platinum treatment. Patients and Methods: A multicenter, open-label, single-arm, phase II study in patients with epidermal growth factor receptor–expressing NPC who progressed on or within 12 months after termination of platinum-based chemotherapy for recurrent or metastatic disease. Cetuximab was administered at an initial dose of 400 mg/m 2 followed by weekly doses of 250 mg/m 2. Carboplatin area under the curve 5 was administered every 3 weeks up to a maximum of eight cycles. Results: Sixty patients were enrolled (46 males, 14 females; median age, 44.5 years; range, 23 to 64 years), and all patients were included in the intent-to-treat and safety analyses. Of the 59 patients assessable for efficacy, there were seven partial responses (11.7%), 29 patients (48.3%) with stable disease, and 23 patients (38.3%) with progressive disease, giving an overall response rate of 11.7% (95% CI, 4.8% to 22.6%). The median time to progression was 81 days in all patients and was longest in the group of patients with a confirmed response (173 days). The median overall survival time was 233 days in all patients. Six patients (10%) experienced serious treatment-related adverse events. Grade 3 or 4 toxicities occurred in 31 patients (51.7%); of these patients, only 19 (31.7%) were considered to have toxicity related to cetuximab. Conclusion: Cetuximab in combination with carboplatin demonstrates clinical activity and an acceptable safety profile in heavily pretreated patients with recurrent or metastatic NPC who had previously experienced treatment failure with platinum-based therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationStatus of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J., & Baselga, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,255
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Ciardiello, F., & Tortora, G. (2001) · PubMed · Cited by 977
Huang, S., Bock, J. M., & Harari, P. M. (1999) · PubMed · Cited by 714
Fan, Z., Baselga, J., Masui, H., et al. (1993) · PubMed · Cited by 431
Targeting the epidermal growth factor receptor for cancer therapy.
Mendelsohn, J. M. (2002) · PubMed · Cited by 414
Prewett, M. C., Hooper, A. T., Bassi, R., Ellis, L. M., Waksal, H. W., & Hicklin, D. J. (2002) · PubMed · Cited by 352
Ciardiello, F., Bianco, R., Damiano, V., Lorenzo, S. D., Pepe, S., Placido, S. D., Fan, Z., Mendelsohn, J. M., Bianco, A. R., & Tortora, G. (1999) · PubMed · Cited by 332
Shin, D. M., Donato, N. J., Perez-Soler, R., Shin, H. J. C., Wu, J. Y., Zhang, P. G. Y., Lawhorn, K., Khuri, F. R., Glisson, B. S., Myers, J. N., et al. (2001) · PubMed · Cited by 298
Cited by
Chua, M. L. K., Wee, J. T. S., Hui, E. P., & Chan, A. T. C. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00055-0 · Cited by 1,236
Self-citationNCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
Colevas, A. D., Yom, S. S., Pfister, D. G., Spencer, S., Adelstein, D., Adkins, D., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0026 · Cited by 614
Ma, B. B. Y., Lim, W.-T., Goh, B.-C., Hui, E. P., Lo, K.-W., Pettinger, A., Foster, N. R., Riess, J. W., Agulnik, M., Chang, A. Y. C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0388 · Cited by 451
Self-citationPrognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis
Liu, N., Chen, N.-Y., Cui, R.-X., Li, W.-F., Li, Y., Wei, R.-R., Zhang, M.-Y., Sun, Y., Huang, B.-J., Chen, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70102-x · Cited by 293
Elser, C., Siu, L. L., Winquist, E., Agulnik, M., Pond, G. R., Chin, S. F., Francis, P., Cheiken, R., Elting, J., McNabola, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2871 · Cited by 252
Metadata
- Authors
- Chan, A. T. C., Hsu, M.-M., Goh, B. C., Hui, E. P., Liu, T.-W., Millward, M. J., Hong, R.-L., Whang-Peng, J., Ma, B. B. Y., To, K. F., Mueser, M., Amellal, N., Lin, X., & Chang, A. Y.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-05-20
- Volume
- 23
- Issue
- 15
- Pages
- 3568-3576
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2095617994
- Cited by
- 287
- References
- 16
- FWCI
- 17.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma. https://app.cochat.ai/papers/10.1200/jco.2005.02.147
- The paper
- Chan, A. T. C., Hsu, M.-M., Goh, B. C., Hui, E. P., Liu, T.-W., Millward, M. J., Hong, R.-L., Whang-Peng, J., Ma, B. B. Y., To, K. F., Mueser, M., Amellal, N., Lin, X., & Chang, A. Y. (2005). Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.02.147
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.